Research programme: antibody therapeutics - Sutro Biopharma

Drug Profile

Research programme: antibody therapeutics - Sutro Biopharma

Alternative Names: anti CD 74 antibody drug conjugates - Sutro Biopharma; DBCO-Alexa647-conjugated SP7219; SP 7219; SP 7675; SP 7676; STRO 001; STRO-002

Latest Information Update: 29 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sutro Biopharma
  • Class Antibodies; Bispecific antibodies; Drug conjugates; Immunoconjugates
  • Mechanism of Action Folate receptor 1 antagonists; Invariant chain inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 22 Jun 2017 Pharmacodynamics data from a preclinical in-vitro study in Cancer presented at the 22nd Congress of the European Haematology Association (EHA-2017)
  • 03 Apr 2017 Sutro Biopharma announces intention to submit IND for STRO 001 to US FDA for Cancer by end of 2017
  • 03 Apr 2017 Sutro Biopharma plans a clinical trial for STRO 001 for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top